BioPharmSignal logoBioPharmSignal

Biotech News

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.Conference / presentation

Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL)

Related news

IOVAIovance Biotherapeutics, Inc.2026-10-26 11:00 EST

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

IOVAIovance Biotherapeutics, Inc.2026-10-29 11:00 EST

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

REGNRegeneron Pharmaceuticals2026-11-02 21:05 EST

Regeneron Announces Investor Conference Presentations

BNTXBioNTech2026-10-20 10:45 EST

BioNTech veröffentlicht am 3. November 2026 Ergebnisse für das dritte Quartal 2026 und informiert über operativen Fortschritt

View all latest news

Iovance Biotherapeutics, Inc.

Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients...

Recent company news

IOVAIovance Biotherapeutics, Inc.2026-11-05 12:00 EST

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

IOVAIovance Biotherapeutics, Inc.2026-10-29 11:00 EST

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

IOVAIovance Biotherapeutics, Inc.2026-10-28 23:00 EST

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

IOVAIovance Biotherapeutics, Inc.2026-10-27 11:00 EST

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

IOVAIovance Biotherapeutics, Inc.2026-10-26 11:00 EST

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

Stock data

Close
7.74 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States